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SUMMARY 
Historical and laboratory data from the first two hundred twenty-nine patients 
who were evaluated in the Renal Stone Clinic at the Yale-New Haven Medical Center 
were analyzed according to type of renal calculus, in an attempt to examine various 
risk factors leading to the development of the specific type of stone. Three patients 
had cystine stones! six patients had uric acid stones! nine patients formed 
magnesium ammonium phosphate stones! seventeen formed calcium phosphate stones! 
and two hundred one formed calcium oxalate or mixed calcium stones. The major focus 
of this analysis was on the identification of preventable risk factors in patients 
with the garden-variety calcium oxalate stone. One or more risk factors were 
identified in the vast majority of these patients, and several novel aspects of 
certain risk factors were discovered. 

INTRODUCTION 
Renal stone disease is a medical condition of far more than academic interest. 
Occurring in approximately three per cent of the American population, renal stones 
account for one in every 1000 hospital admissions in the United States. (Broadus, 
1981) The colic that renal calculi can cause is said to be "one of the more severe, 
frightening pains encountered in medical practice." (Walker, 1980) Because of the 
growing body of data implying that nephrolithiasis is often preventable, great effort 
has been expended in the characterization of the disease and the habits that may 
cause the disease. Although the growing body of knowledge is continually expanding, 
many of the treatment modalities for nephrolithiasis have not kept up with the grow¬ 
ing knowledge base. For that reason this study was designed to examine the records 
of the first 229 patients at the Yale-New Haven Medical Center Renal Stone Clinic to 
complete a metabolic screening evaluation for underlying causes of nephrolithiasis. 
Renal stone disease, in essence, is a constellation of several entities. In gener¬ 
al the term "nephrolithiasis" refers to calculi primarily composed of cystine, magnes¬ 
ium ammonium phosphate, uric acid, calcium phosphate, calcium oxalate, or mixed 
calcium oxalate-calcium phosphate. (Mixed calcium oxalate-calcium phosphate stones 
refer to those calculi which are mostly composed of calcium oxalate, but have a cal¬ 
cium phosphate composition greater than twenty per cent.) As will be seen, the 
crystallographic stone type forms a rational basis by which to subdivide patients 
with renal stone disease, and the following schema will provide the organizational 
format for this thesis: 
I. Cystine Stones 
II. Uric Acid Stones 
III. Magnesium Ammonium Phosphate Stones 
IV. Calcium Phosphate Stones 
V. Calcium Oxalate and Mixed Calcium Stones 
A. Calculi as a secondary manifestation of other illnesses 
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B. Calculi as a primary disease—"garden-variety" stones 
Several points regarding this schema are noteworthy at this juncture. Although 
this thesis will concentrate mostly on calcium oxalate stones, it will review the other 
stone types and make a clear distinction between calcium phosphate and calcium ox¬ 
alate stones, a distinction often not made in the existing literature on the subject. 
The category of calcium oxalate stones and mixed calcium stones will be considered 
in two parts. As secondary manifestations of other illnesses (only a small portion of 
the total are in this category), their underlying pathophysiology will be reviewed. For 
calcium oxalate and mixed calcium stones forming without a known primary illness, 
the risk factor concept will be introduced, highlighting the risk factors of family his¬ 
tory, hypouresis, hypercalciuria, and hyperuricosuria. Although treatment and 
outcome are beyond the scope of this study, the risk factor approach to renal stone 
disease allows the hope that elimination of some or all of the statistical risk factors 
may, in fact, prevent or significantly lower the subsequent incidence of renal stone 
formation in this patient population. 
Cystine Stones 
Cystine is the least soluble of all of the naturally occurring amino acids. In nor¬ 
mal urine its maximum solubility is approximately 300 mg/L. These stones are formed 
only by homozygous cystinurics whose genetic defect in renal tubular amino acid re¬ 
absorption causes them to excrete 600 to 1400 mg of cystine daily. With the urine 
being oversaturated with cystine, spontaneous formation of cystine crystals will 
take place, contributing to the formation of cystine stones. An alkaline urine can 
increase the solubility of cystine, but disorders of urine acidification alone are not 
responsible for cystine stone formation. 

-6- 
Because the intestinal transport system for cystine is either absent or defec¬ 
tive in almost all patients with cystinuria, the cystine that is excreted in the urine 
must be derived endogenously from the hepatic metabolism of dietary methionine. 
Because the transport system is missing in the renal tubules, likewise, cystine reab¬ 
sorption does not take place and cystinuria results. 
Any patient with a history of recurrent renal calculi is a potential cystine stone 
former. A diagnosis may be suggested by an early age of onset of stone disease. 
Definitive diagnosis is made by stone analysis, demonstration of cystine 
crystalluria, or by quantitative urinary amino acid analysis. 
This study will reinforce the statement that hypercystinuria is associated with 
formation of cystine stones and indicate its rarity within a renal stone clinic 
population. 
Uric Acid Stones 
Uric acid stones are usually pure, affect mostly middle-age males, and account 
for approximately five per cent of stone disease in Western countries. As the final 
breakdown product of purine metabolism in humans, uric acid production and excretion 
are affected by dietary purines as well as endogenous purine production. Because the 
rate of metabolism of endogenous purines in a given individual remains constant un¬ 
der normal circumstances, variation in uric acid production is largely a function of 
dietary purine intake. Uric acid is excreted into the urine through a complex system 
of proximal tubular reabsorption, tubular secretion, and post-secretory reab¬ 
sorption. Tubular reabsorption is the dominant quantitative process governing the 
amount of uric acid excreted. 
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Whether the urine uric acid will precipitate to form a stone is largely a function 
of the ambient urinary pH. An acidified urine will tend to shift the equilibrium be¬ 
tween uric acid and its urate salt in the direction of the acid form. Uric acid is far 
less soluble than its urate salt. Because the pK of uric acid is 5.75—in the center 
of the physiological range for urine pH—the relative concentrations of uric acid and 
urate salts are exquisitely sensitive to urine pH. For example, given a urine uric acid 
excretion of 1000 mg per day at a pH of 6.0, the amount of free uric acid present 
would be 360 mg. But at a pH of 5.0, the amount of free uric acid present would be 350 
mg. Since the ultimate solubility of uric acid in urine is about 100 mg/L at pH of 5.0, 
and 1500 mg/L at pH of 7.0, the shift in pH by one could be the difference between 
precipitation and solubility for uric acid. 
Diagnosis is best made through laboratory analysis of a stone. Because uric 
acid stones are radiolucent, they can only be suspected from an intravenous pyelo- 
gram. This study will support the concepts that hyperuricosuria and hypouresis 
should be considered as physical chemical risk factors associated with uric acid 
stones. 
Magnesium Ammonium Phosphate Stones 
Magnesium ammonium phosphate stones (MAP) stones are a relatively rare but 
extremely morbid type of renal calculi. As with cystine and uric acid stones, MAP 
stone formation is a logical consequence of physical chemistry. MAP stones are com¬ 
posed of struvite (MgNH^PO^eH^Q) admixed with small amounts of carbonate-apatite 
(Ca^(PO^)gCO^.). In sterile urine, the solubility product of struvite is never ex¬ 
ceeded, and MAP stones do not form. The pathological presence of urease-producing 
bacteria can cause an alkaline urine and increased concentrations of ammonium, car- 
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bonate, and relatively insoluble, multiply charged phosphate ions. These charges 
oversaturate the urine with respect to both magnesium ammonium phosphate and car¬ 
bonate-apatite, quickly leading to struvite stone formation. Urease acts on urea in 
the following sequence: 
Urea (CO(NH.L) + H.O ====Urease====> 2 NH + CO. 
L. L. L. O L- 
2 NH3 + 2 H20 <========> 2 NH4+ + 2 OH~ 
C0o + H O <========> H CO <========> H+ + HCO ~ 
2 2 2 3 3 
H+ + HCO./ + 2 OH" <========> CO~2 + 2 H O 
u* W 
With some ninety per cent of clinical isolates of Proteus, Staphyloccus aureus, and 
Bacteroides species producing urease and some thirty per cent of Klebsiella and 
Pseudomonas acting in the same manner, all of these bacterial strains have been 
clinically implicated in series of MAP stone patients. Proteus species, however, have 
been the most common isolate. 
The basic prerequisite for a MAP stone is an abnormality that predisposes to 
urinary tract infection. These derangements include megaureter, ureteral reflux or 
obstruction, ileal conduits, nephrostomy drainage, medullary sponge kidney, neuro¬ 
genic bladder, or the presence of any non-MAP stone. Diagnosis is made thorugh 
radiologic visualization of a staghorn calculus or by crystallographic analysis of 
stone material. This study confirms previous reports that in a substantial proportion 
of MAP stone patients urine colony counts of urease-producing bacteria were less 
than 100,000 per milliliter. (Broadus, 1981). It reveals, however, a lower incidence of 
associated abnormalities associated with non-MAP stone formation than reported by 
others. (Smith, 1976) 
Calcium Phosphate Stones 
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Unlike some conventional considerations of nephrolithiasis, this study empha¬ 
sizes that calcium phosphate stones (a relatively rare phenomenon) sthould be 
considered as distinct from the common calcium oxalate stone. (Coe, 1973, Coe, 1974, 
Ullmann, 1982). 
An essential feature of calcium phosphate stones is that they form in a sterile 
alkaline urine. The importance of the urine pH is rarely appreciated. With the con¬ 
centration of HPO^ ^ rising rapidly in the presence of increasing pH, the components 
of a calcium phosphate stone reach concentrations of supersaturation, and ultimate¬ 
ly oversaturation, which forces calculus formation. (Broadus, 1981, Nordin, 1973). 
Since, as this study confirms, calcium phosphate stones only form in a sterile alka¬ 
line urine, their presence suggests an underlying mechanism associated with a 
persistently alkaline urine. 
A normal kidney maintains the pH of the extracellular fulids by entirely reclaim¬ 
ing the filtered load of bicarbonate and by excreting a quantity of fixed acid equal 
to that produced endogenously. Almost all of the filtered bicarbonate is reabsorbed 
in the proximal tubule. The distal tubule operates to remove remaining bicarbonate 
and set the final urinary pH. The normal kidney can achieve a final urinary pH of 5.0 
or lower. (Brenner, 1980) 
One acidification disorder seen in calcium phosphate stone patients is complete 
distal renal tubular acidosis (RTA). Patients with this illness are rarely able to pro¬ 
duce a urine with a pH of less than 5.5. RTA can be caused by genetic factors, 
Sjogren's syndrome, medullary sponge kidney, Ehlers-Danlos syndrome, amphotericin, 
obstructive uropathy, and several other miscellaneous conditions. (Kathpalia, 1980) 
The resulting acidosis inhibits citrate production in the renal cortex, leading to 
a reduced citrate excretion rate. Because the citrate can then have less of an ef- 

-10- 
fect on binding urinary calcium into soluble complexes, RTA acts as a double-edged 
sword to cause calcium phosphate stone crystallization. RTA may also stimulate hy- 
percalciuria by causing a defect in distal tubule calcium reabsoprtion or through 
mobilization of bone calcium, as bone minerals are used to buffer serum acids. Incom¬ 
plete distal RTA, in which there is no systemic acidosis although the urine is 
alkaline, might also lead to calcium phosphate stone formation, but this question was 
not evaluated in detail in the present study. (Broadus, 1981) 
Medications may also predispose a patient to form calcium phosphate calculi. 
(Parfitt, 1969) As a carbonic anhydrase inhibitor, acetazolamide will inhibit proximal 
tubular bicarbonate reabsorption, simultaneously inhibit citrate production, decrease 
the excretion of ammonium ion and titratable acid, and increase the urine 
alkalinity—in effect causing secondary or "exogenous" RTA. Chronic low-dose inges¬ 
tion of calcium or sodium bicarbonate antacids may cause urine alkalinity and 
calcium phosphate stones as well. (Broadus, 1981) 
Diagnosis can be made only through crystallographic analysis. 
Calcium Oxalate and Mixed Calcium Stones 
Stones containing calcium oxalate make up the lion's share of the stones. This 
category was defined as including patients who met at least one of the following cri¬ 
teria: 1) crystallographic analysis of a renal calculus which showed that the stone 
was composed of at least fifty per cent calcium oxalate, and/or 2) radiologic examin¬ 
ation showing the presence of a radioopaque stone (or stones) in a patient with no 
suggestive evidence of another stone type. Of the 179 patients in this group, 156 
(87%) satisfied the first definition. Predominantly males are afflicted with this stone 
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type. (Johnson, 1979) The risk factor concept may be applied most fruitfully to this 
population. 
A short review of the physical chemistry associated with the formation of 
calcium oxalate-containing is in order. The underlying concept to be addressed is the 
equilibrium between the solid crystal and dissolved ionic phases of a solute such as 
calcium oxalate. In an "undersaturated" system, the addition of solid phase material 
to the system leads to the complete dissolution of the solid material. When sufficient 
solid phase material is added, however, the system becomes "saturated." In this 
condition, added solid phase material can only partially be dissolved into its ionic 
components. If one removes the solid from this system, one is left with a "saturated" 
solution of ions dissolved in water. When sufficient quantities of a concentrated 
solution of any of the solute components are added to the "saturated" solution, then 
the "saturated" solution will become "oversaturated," and solid crystals will 
spontaneously nucleate (i.e. precipitate) out. Although the case of calcium oxalate in 
urine is a far more complex system than that in water (involving numerous soluble 
components and ion-ion interactions) the aqueous system may be seen as a model for 
precipitation of calcium oxalate crystals in urine. When sufficient quantities of a 
concentrated solution of any of the solute components (e.g., a hypercalciuric urine in 
the distal renal collecting tubules is added to a "saturated" urine in the renal 
collecting ducts), oversaturation may occur and calcium oxalate stone formation may 
occur. Because calcium oxalate is less soluble in normal urine than either calcium 
phosphate, uric acid, magnesium ammonium phosphate, and cystine, it is more 
sensitive to abnormal urinary perturbations than any other stone type. This fact 
likely accounts for the great frequency of calcium oxalate stone disease observed 
among patients with nephrolithiasis (Broadus, 1981). This fact also underlies the 
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clinical utility of the risk factor concept in practice, some of these risk factors 
including abnormalities which have no direct influence on calcium or oxalate 
metabolism per se. 
To facilitate consideration of this stone type, the following etiologic and 
epidemiologic schema will be followed: 
I. Calcium Oxalate Stones Secondary to Established Primary Illnesses 
A. Primary Hyperparathyroidism 
B. Enteric Hyperoxaluria 
C. Renal Tubular Acidosis 
D. Sarcoidosis 
E. Others: Vitamin D Excess, Immobilization, Uncontrolled Diabetes 
Diabetes Mellitus, Glucocorticoid Excess, Thyrotoxicosis 
II. Primary Risk Factors for Garden-Variety Calcium Oxalate Stones 
A. Family History 
B. Hyperoxaluria 
C. Inadequate Urine Volume 
D. Hyperuricosuria 
E. "Idiopathic” Hypercalciuria 
1. "Absorptive" Hypercalciuria 
2. "Renal" Hypercalciuria 
3. "Dietary" Hypercalciuria 
F. Multiple Risk Factors 
Brief consideration will be given to the primary diseases producing secondary 
nephrolitihiasisj these made up only a small portion of a calcium oxalate stone popu¬ 
lation. The garden-variety stone—lacking a known primary etiology—will then be 
considered separately. Based primarily on the physical chemical properties described 
above, individual risk factors will be considered—much in the manner for which such 
variables as cigarette smoking, serum cholesterol, and hypertension are commonly 
evaluated in the case of coronary artery disease. Etiologies of "idiopathic" hyper¬ 
calciuria will receive particular attention, with emphasis placed upon the importance 
of "absorptive" hypercalciuria and the newly-defined entity "dietary" hypercalciuria. 
Primary Hyperparathyroidism 
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Although there will be little of novel interest to say regarding primary hyperpa¬ 
rathyroidism, a number of basic points will be reemphasized. This disorder is an im¬ 
portant primary disorder of renal stone disease. Indeed, some fifty per cent of 
hyperparathyroid patients have renal calculi as their presenting complaint. (Broadus, 
1981) The key point meriting emphasis is that certain patients with primary hyperpa¬ 
rathyroidism manifest disproportionate hypercalciuria vis-^-vis the fasting serum 
calcium concentration, and it is this subpopulation which is predominantly at risk for 
stones. The principal pathophysiological correlate explaining the disproportionate 
hypercalciuria is the circulatory concentration of 1,25-(OH)^D, so that the 
hypercalciuria is predominantly "absorptive" in nature. (Broadus, 1980, 1981) 
Enteric Hyperoxaluria 
Enteric hyperoxaluria has been considered as a distinct entity since 1972, fol¬ 
lowing recognition that hyperoxaluria and a predisposition to nephrolithiasis were 
seen in a variety of gastrointestinal disorders, including Crohn's disease, nontrop- 
ical sprue, chronic pancreatitis and biliary tract disease, blind loop syndrome, and 
following ileal resection or jejunoileal bypass, but not including ulcerative colitis. 
This study will echo the association between enteric hyperoxaluria and renal calculi, 
but will not explore this relatively minor cause of stone disease further. The patho¬ 
physiology is thought to involve a colonic hyperabsorption of dietary oxalate. The 
particular mechanism of this hyperabsorption has not been established. By predis¬ 
posing the urine to oversaturation, enteric hyperoxaluria is thought to stimulate 
calcium oxalate stone formation. (Smith, 1980) 
Renal Tubular Acidosis 
These stones are significantly composed of calcium phosphate and were 
considered in a previous section. 
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Sarcoidosis 
Hypercalciuria has been noted in approximately forty per cent of patients with 
sarcoidosis, and this disease has been associated with calcium oxalate stone forma¬ 
tion. (Winnacker, 1963, Broadus, 1981) The hypercalciuria is a function of dietary 
calcium intake, renal function, bone resorption, and abnormal rates of conversion of 
25-OH D to l^S-COHi^D. (Papoulos, 1979) By promoting an oversaturated urine with 
respect to calcium, sarcoidosis can predispose to calcium oxalate stone formation. 
Diagnosis of sarcoidosis is made from radiographic, chemical, and biopsy evidence of 
the disease. This study will confirm that this disease is infrequently seen in a stone 
population. (Broadus, 1931) 
Other Secondary Hypercalciurias 
Other primary diseases have been suggested as predisposing patients to hyper¬ 
calciuria and, rarely, nephrolithiasis, although they were not observed in this series. 
(Broadus, 1931) These diseases include "excess Vitamin D intake," immobilization, 
rapidly progressive osteoporosis, malignant osteolysis, medullary sponge kidney, un¬ 
controlled diabetes mellitus, glucocorticoid excess, thyrotoxicosis, acromegaly, and 
furosemide administration. All have been variously associated with hypercalciuria, 
but their relationship to stone formation has been poorly studied. 
Family History 
Family history is strongly associated with this disease. No genetic markers have 
yet been identified, but family history confers a definite statistical risk. (Resnick, 
1963) This study confirms the high rate of positive family history for renal stones 
among patients with renal stones. 
Hyperoxaluria 
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As described in the section on physical chemistry, hyperoxaluria, theoretically, 
would predispose a patient to formation of calcium oxalate stones. Because urine 
oxalate was only studied systematically in patients suspected of having enteric 
hyperoxaluria, and not in the entire stone population, this study did not determine 
whether hyperoxaluria was a significant risk factor in patients with garden variety 
calcium oxalate stone disease. 
Hypouresis 
As calcium oxalate in normal urine just borders on the edge of oversaturation, 
hypouresis is yet another risk factor that can play a critical role in pathogenesis. 
An inadequate urine output might be sufficient cause for calcium oxalate becoming 
oversaturated in urine, compelling calcium oxalate crystal formation. (Pak, 1980) The 
common prevalence of inadequate fluid intake and resulting low urinary output in 
Israeli settlement towns of the 1950's was, indeed, suggested as the cause of the 
high incidence of renal stone disease in that country. (Frank, 1959) In the present 
study, an "inadequate" urine was considered to be less than one liter per day. 
Hyperuricosuria 
A risk factor that will be emphasized is hyperuricosuria. The entity of hyperur- 
icosuric calcium oxalate nephrolithiasis was initially recognized in the 1970's. (Coe, 
1973, Coe, Kidney International, 1978, Coe, Nephrolithiasis, 1978). A reliable mecha¬ 
nism for this process has not yet been established, although there have been reports 
that epitaxy might play a role. According to this theory, when different crystals 
types share a similar lattice structure, saturation with one solute type might induce 
heterogeneous nucleation (i.e. precipitation) and/or crystal growth of another type 
of solute. Since calcium oxalate, uric acid, and monosodium urate crystals have been 
reported to share similar lattice structures, this might be the mechanism by which 
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hyperuricosuria favors production of calcium oxalate stones. (Lonsdale, 1968) De¬ 
tails of purine metabolism were considered earlier under Uric Acid Stones. What 
makes assessing this risk factor especially difficult is that statistically precise 
limits for normal uric acid excretion have not been established. Because intestinal 
absorption of purines is not regulated, hyperuricosuria is frequently a simple 
function of purine intake. This study employed the upper normal limit recommended by 
others, even though it was recognized that these limits were not statistically based. 
These criteria defined hyperuricosuria as uric acid excretion of more than 800 mg per 
day in males and 750 mg per day in females. (Coe, Kidney International, 1978). Three 
potential mechanisms for hyperuricosuria in patients with oxalate stone disease are: 
1) endogenous uric acid overproduction, 2) purine gluttony, and 3) increased frac¬ 
tional excretion of uric acid. (Broadus, 1978) This study will echo that little support 
for the third hypothesis exists. That a majority of patients with hyperuricosuria are 
normouricemic suggests that two subpopulations might exist, one of overproducers, 
the other of purine gluttons. Clearly, exogenous purines would influence uric acid 
excretion in both subpopulations, and the line between them is thin. 
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"Idiopathic" Hypercalciuria 
The risk factor to which particular attention will be paid is hypercalciuria. An 
association between hypercalciuria and calcium stone formation has been known 
since 1939. (Flocks, 1939) Unfortunately, delineating the nature of the hypercalciuria 
has progressed slowly. Since 1958, the renal stone literature has contended with the 
term "idiopathic hypercalciuria" to describe those hypercalciuric patients for whom 
no primary disease could readily be identified as causing their hypercalciuria. These 
patients were thought to have normocalcemic hypercalciuria and a tendency to hypo¬ 
phosphatemia. They were noted to have increased intestinal calcium absorption, 
which, at the time, was considered secondary to a "renal leak" of calcium. (Henneman, 
1958) In the ensuing quarter-century, debate has raged over the mechanisms and fre¬ 
quencies of subgroups of "absorptive," "resorptive," and "renal" hypercalciurias that 
were thought to comprise the idiopathic hypercalciurias. (Broadus, 1934).This study 
will emphasize the prevalence of the entity known as "absorptive hypercalciuria." 
In practice "hypercalciuria" is difficult to define in a meaningful way because 
there are so many dietary influences on calcium excretion. On a "free" or undefined 
diet, calcium excretion can be increased by dietary protein, sodium, and carbohyd¬ 
rate, and decreased by dietary oxalate and phosphorus. Dietary calcium itself can 
profoundly increase urinary calcium, especially in renal stone formers. (Peacock, 
1967, Lemann, 1979) 
A "hypercalciuric" patient was defined in this study as one who met at least one 
of the following criteria: On either or both of the protocol diets (see Appendix Two), 
they had 1) a calcium excretion rate of greater than 250 mg per day in females; 2) 
greater than 300 mg per day in males; or 3) greater than 4 mg per kg per day in either 
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sex. These limits are consistent with those recommended by most investigators within 
the United States. (Broadus, 1931) 
The most common subtype of idiopathic hypercalciuria associated with the “typi¬ 
cal oxalate stone" is absorptive hypercalciuria. As currently understood, this 
disease involves increased circulating levels of IjZS-COHi^D, leading to intestinal 
hyperabsorption of calcium. These patients have an increased gut absorption of cal¬ 
cium that presents the normal kidney with an increased load of calcium, which is then 
excreted, causing hypercalciuria. (Coe, Nephrolithiasis, 1978, Broadus, 1981, 
Broadus, 1984) This study examined one proposed mechanism for absorptive hypercal¬ 
ciuria, involving a primary renal tubular phosphate leak. (Lemann, 1980) According to 
theory, for which this study found no support, the phosphate leak leads to a reduc¬ 
tion in TmP/GFR and serum phosphate concentrations and secondary increases in 
IjZS-tOHl^D and intestinal calcium absorption. A full discussion of the phosphate 
leak hypothesis is beyond the scope of this thesis. 
Renal hypercalciuria is thought to involve a primary defect in renal tubular cal¬ 
cium reabsorption. The tubular calcium losses lead to secondary hyperparathyroid¬ 
ism, the theory goes, stimulating 1,25-(OH).7D production, calcium absorption, and 
reducing TmP/GFR and serum phosphorous. (Broadus, 1979, Broadus, 1981). This study 
found no evidence of such a mechanism. 
Patients with so-called "idiopathic" hypercalciuria have been noted to increase 
their urine excretion of calcium markedly in response to increasing dietary calcium 
from a low-normal to a high-normal level. In contrast, normal subjects show a minimal 
increase under these conditions. (Broadus, 1979) In this series, it was presumed that 
hypercalciuric patients would manifest a greater degree of hypercalciuria on the 
fixed (1000 mg) calcium diet than on the "free" diet sample (typically with 3 lower in- 
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take of calcium). As will be seen, a substantial minority of patients did not display 
such a pattern. Rather, they displayed more marked hypercalciuria on the "free" diet 
than on the fixed high-normal calcium diet, even though, on the average, the calcium 
intake on the fixed diet was some one-third higher than that on the "free" diet. Most 
of this subset of patients did not have an identifiable metabolic abnormality on de¬ 
tailed testing. It follows that dietary factors other than calcium must have influ¬ 
enced the results for calcium excretion on the "free" diet, and the term "Dietary 
Hypercalciuria" is introduced in connection with these patients. The patients consid¬ 
ered in this category were those who displayed hypercalciuria on one of the protocol 
diets and whose calcium excretion was more than 50 mg/day higher on the "free" diet 
as compared with the fixed 1000-mg calcium diet, along with those patients who, par¬ 
adoxically, were hypercalciuric on both diets, but whose performance on a calcium 
tolerance test indicated that they did not have absorptive hypercalciuria. Together 
these two subgroups were considered as one cohort. Because such variables as diet¬ 
ary calcium, phosphorus, protein, and sodium are not set in the "free" diet, while they 
are regulated in the fixed diet, the hypothesis that one or more of these dietary 
factors might influence the result on the free diet urine calcium was considered. 
Diagnosis of hypercalciuric etiologies was made through measurements of fast¬ 
ing calcium excretion, 24-hour calcium excretion, total serum calcium, ionized serum 
calcium, serum immunoreactive PTH, nephrogenous cAMP, and total cAMP excretion, 
as detailed in the methods sections below and in Appendix Two. 
METHODS 
The Stone Clinic: The Yale-New Haven Medical Center Renal Stone Clinic is a 
weekly outpatient referral clinic in New Haven, Connecticut. Since its inception in 
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1977, the clinic has been conducted by a minimum of three internists, a nurse, and a 
dietician. 
The Patient Population: Although a small number of patients were self-referred 
to the clinic, the vast majority were either referred by a urologist, a general practi¬ 
tioner, or an internist. The clinic has been in continuous operation since 1977. This 
study examines the historical record of the first 2clinic patients who had been 
evaluated as of October 1982. 
Screening Schedule: The evaluation screen at the stone clinic was established 
to take place over two clinic visits. The purpose of the initial visit was to determine 
all historical, radiological, and physical exam parameters relating to the patient's 
stone disease, to obtain serum and urine specimens reflecting the "free" diet, and to 
instruct the patient on the nature of the fixed diet, from which urine calcium was 
quantified upon the second clinic visit. The purpose of the second clinic visit was to 
inform the patient of the results of tests conducted on the first visit and to plan 
future tests and/or therapy. In the case of unexplained hypercalciuria, this would 
involve scheduling a calcium tolerance test. If radiological information available at 
the first visit was unsatisfactory, a set of KUB and oblique abdominal films was 
scheduled for the second visit. Therapy might commence with dietary counseling 
and/or medication. 
Initial Evaluation'. Prior to arrival at the clinic for his first appointment, each 
patient was sent a copy of a "First Renal Stone Clinic Visit" form. (See Appendix Two) 
Along with the form is sent a collapsible 24-hour urine container and instructions for 
collecting a one-day sample. Each patient was instructed to arrive to the clinic in a 
fasting state. On admission to the clinic, a complete history and physical examina¬ 
tion was performed on each patient. Particular attention was paid to the history of 

-21- 
stone events, dietary, and associated factors as noted on the forms in Appendix Two. 
When permission was granted to study a patient's family history, a detailed pedigree 
was prepared for each first-degree relative of the affected patient. Patients with 
at least one first-degree relative with a reported history of passage of a renal cal¬ 
culus were considered as having a positive family history. A detailed, quantitative, 
dietary history was obtained by a trained nutritionist, using the diet history form in 
Appendix Two. This history corresponded to the day of the "free" urine collection. 
Radiological evaluation: An intravenous pyelogram (IVP) from within one year of 
intake was examined on every patient, whenever possible. Particular attention was 
paid to assessing anatomical abnormalities predisposing to stone formation and de¬ 
termination of the quantity and quality of any stones present. Flat abdominal and 
oblique films were obtained whenever old films were insufficient for reliable 
diagnosis of stone number, type, and/or location. 
Laboratory evaluation: Results of previous stone analyses were examined and, 
whenever possible, a representative recent stone was sent for crystallographic 
analysis. At the patient's inital clinic visit, fasting blood levels of calcium, phos¬ 
phorus, bicarbonate, chloride, creatinine, and uric acid were determined. The inital 
twenty-four hour urine specimen on a "free" or undefined diet (as noted on the diet 
history form) was analyzed quantitatively for creatinine, calcium, sodium, phos¬ 
phorus, magnesium, uric acid, and TmP/GFR. In many cases the fractional excretion 
of uric acid was also determined. Urine volumes were also noted and the creatinine 
quantitated to ensure completeness of the collection. A cle3n-catch, spot, fasting 
urine was also obtained for culture and for pH determination by nitrazine paper or pH 
meter. In all cases a cystine screen (nitroprusside) was performed on this specimen. 
If the initial urinary pH was greater than 5.5, the patient was given nitrazine paper 

for recording serial urinary pH values in order to document that the urine could be 
acidified to a pH of less than 5.5. The average pH of the first eighteen consecutive 
urine samples was designated as the "mean pH." The presence and degree of hyper- 
calciuria were evaluated by instructing patients to collect two twenty-four-hour ur¬ 
ine samples on a "fixed" or defined 1000—mg calcium diet. For this regimen (see 
patient form in Appendix Two) patients were instructed by the dietician to limit their 
protein intake to approximately one gram per kg of body weight per day, to limit their 
sodium intake to approximately one hundred milliequivalents per day, to eliminate 
dairy products, and to supplement the diet with calcium gluconate tablets, two grams, 
three times daily with meals. The net calcium intake on the fixed diet was approxi¬ 
mately 1 gram per day, and the urine collections were obtained after at least one full 
day on the diet. Patients who were hypercalciuric on either diet or both and for whom 
no primary cause for the hypercalciuria was identified were then evaluated with an 
"Oral Calcium Tolerance Test" described in Appendix Two. (Broadus, 1973) The calce- 
mic response (in normal individuals it is usually less than 0.4 mg/dL) is an index of 
calcium "tolerance." The calciuric response served as an index of intestinal calcium 
absorption. Induced changes in nephrogenous cAMF' or total cAMP excretion served to 
indicate parathyroid suppressibility, as it is the best clinical means of measuring 
circulating parathyroid hormone activity. (Broadus, 1981) Absorptive hypercalciuria 
was diagnosed in patients who met the strict criteria described in Appendix Two. 
(Broadus, 1934). 
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RESULTS 
The stone population was made up of 163 males and 60 females. This sex distri¬ 
bution was almost identical to that reported (70:30) in a previous study of a large 
group of stone patients. (Prince, 1960) The mean age of the stone clinic patients at 
the time of their first stone episode was 34 years. (See Figure One) The mean fre¬ 
quency of previous stone episodes since the first stone episode among stone patients 
was two per year. (See Figure Two) Two patients had sarcoidosis, three had cystin- 
uria, four had renal tubular acidosis, eight had enteric hyperoxaluria, and ten had 
primary hyperparathyroidism. Of those patients without a known primary disease 
explaining the formation of their calculi, six had uric acid stones, nine had magnes¬ 
ium ammonium phosphate stones, fifteen had calcium phosphate stones, and one 
hundred eighty had calcium oxalate or mixed calcium stones. Eleven patients had more 
than one type of stone. Detailed averages of urinary excretion rates appear in 
Appendix One. 
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FIGURE 1: 
Distribution of Ages At First Stone Episode 
x-axis: age (years)...y-axis: number of patients 
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FIGURE 2: 
Frequency Distribution of Mean Annual Stone Episodes 
x-axis: episodes per year...y-axis: percentage of patients 
One patient's stone frequency fell above the range depicted on the table below. 
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MAP Stones 
Among the nine patients who dev/eloped MAP stones, three (33%) had a positive 
family history for renal stone disease. Although the organism count was higher in 
this group (j-t=45,6Q0) than in the remainder of the stone patients studied (p.=9,9Q0, 
S.D.=74,000, N=195), the difference was not large enough to be significant (p=.G74). A 
positive culture was noted in six of the eight patients for whom a culture result was 
available. In this group of patients, 50% had a bacteriuria count of greater than 
40,000 per milliliter, while only 6% of the remaining stone patients had bacteriuria 
greater than 40,000 per milliliter. Five of the eight patients with culture results 
available had a colony count of less than one hundred thousand per milliliter. (See 
Figures Three and Four) Among the cases where a presumably causative organism 
could be identified, Proteus mirabilis was the dominant organism in four cases, 
Pseudomonas aeruginosa in one, and Enterococcus in one more. 
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FIGURE 3: 
Distribution of Organism Count in MAP Stone Patients 
axis: organisms/ml...y-axis: number of patients whose colony count 
value on the x-axis at the left side of the bar 
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FIGURE 4: 
Distribution of Organism Count in non-MAP Stone Patients 
-axis: organisms/ml...y-axis: number of patients whose colony count equalled the 
value on the x-axis at the left side of the bar 
One patient's colony count was above the range depicted on the chart below. 
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Among these nine patients, five had "urinary tract infection" as their primary 
diagnosis predisposing them to renal calculus formation. One had medullary sponge 
kidney—presumably having an anatomical and functional urinary tract dysfunction 
predisposing to urinary tract infection. One had hypouresis as a risk factor, as well 
as a history of urinary tract infections (documented with repeated urinary cultures), 
thought secondary to chronic nephrolithiasis. One patient had a history of antacid 
abuse and another was hyperuricosuric, both of which were thought to have induced a 
"metabolic" stone formation and undocumented secondary urinary tract infection. The 
TmP/GFR of the MAP stone population (M=2.4) was significantly less (p=.001) than 
that observed in the remainder of the stone population (U=3.1, S.D.=0.7, N=194). 
Uric Acid Stones 
As a group, the uric acid stone population had a significantly (p=.003) lower ur¬ 
ine volume (M=10Q0 ml) than the rest of the 5ten€ patients (//=/£23 ml, S.D.=811, 
N=223). Although 50% of this group had urine volumes less than 1000 ml, only 18% WO 
of 223) of non-uric acid stone formers had such low urine volumes. At this level of 
urine output, hypouresis would be an appropriate term for describing their state. 
Dietary purine intake per kg body weight (U=l .92 mg/kg, S.D.=1.09, N=S) was not 
significantly different than that observed among the rest of the stone population 
(p=l .70 mg/kg, S.D.=1.28, N=211). Three of the six patients also had a history of 
oxalate stones; two of the six had hyperuricosurial one had gout; and one had Crohn's 
disease. When compared to the rest of the stone population, the uric acid stone 
formers had no significant difference (p>.05) in their serum or urinary uric acid 
levels, or in their Fractional Excretion of Uric Acid. The mean urinary pH measured 
for two of the six patients with uric acid stones, was approximately the same as that 
obtained in the non-uric acid stone population (p=5.8, S.D.=0.7, N=107). There were no 
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known patients in this uric acid group who had any of the rare inborn error of 
metabolism diseases that can cause uric acid stones. 
Cystine Stones 
All three of the patients who developed cystine stones in this series had a 
diagnosis of cystinuria. Two of the patients (brothers) had a family history of stone 
disease. The average age of onset of stone episodes was eighteen years. Daily urine 
volumes averaged 1160 ml, and urine cystine averaged 311 rng/day. All of the urine 
cystine concentrations (p=648 mg/L) exceeded the maximum solubility (300 mg/L) of 
cystine in urine. 
Calcium Phosphate Stones 
A total of seventeen patients formed pure or predominantly calcium phosphate 
stones. Two of these had renal tubular acidosis. Of the remaining fifteen patients 
without a "primary" disease process leading to their formation of phosphate calculi, 
two had a history of chronic antacid ingestion, and another had a history of regular 
acetazolamide ingestion. As such, there were a total of twelve patients without a 
readily identifiable source of an alkaline urine that would predispose to calcium 
phosphate stone formation. The mean urinary pH in the seven of these twelve 
patients in whom "mean urinary pH" was determined (M=6.1) was higher (p=.0Q2) than 
that observed in the rest of the studied population (ju=5.3, S.D.=0.7, N=102). There 
was no significant difference (p>.05) between the TmP/GFR in these patients (^=2.9) 
and the rest of the stone population (,U=3.1, S.D.=0.7, N=193). Nor was there any sig¬ 
nificant difference between the serum chloride, serum bicarbonate, or lowest 
recorded urinary pH of these twelve calcium phosphate stone patients and the 
remainder of the stone population. 
Calcium Oxalate Stones 
' It I* 
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With a distribution of 151 males and 47 females in this series having oxalate 
stones, it becomes clear that this type of stone disease has a predilection (p<.05) for 
males (Chi Square Value>3.341). Although oxalate stone disease is a curse of 
industrialized nations, it is the male population, especially, who suffer from the 
curse. 
Renal Tubular Acidosis 
Of the 198 patients with calcium oxalate stones, only one was diagnosed as 
having renal tubular acidosis. 
Sarcoidosis 
Two patients in this series had calcium oxalate stones associated with sarcoid¬ 
osis. Of note was that their serum calcium averaged 10.2 mg/dL and that their 
24-hour calcium excretion on the fixed diet averaged 5.2 mg/kg Wt. 
Enteric Hyperoxaluria 
Eight patients in the calcium oxalate—mixed calcium stone group had enteric 
hyperoxaluria. Not suprisingly, they were noteworthy for having a 24-hour urine 
oxalate (JJ.=74, N=5) that was significantly (p=.G35) greater than that observed among 
the other members of the stone population whose urinary oxalate values were quanti¬ 
fied (J-i=52, N=26). 80% of the patients in this group had a urinary oxalate of greater 
than 55 mg/day. Only 27% (7 of 26) of the remaining stone patients for whom urinary 
oxalate was examined had such high urinary oxalate levels. 
Primary Hyperparathyroidism 
The ten patients with primary hyperparathyroidism in this series included three 
males and seven females. This three to seven sexual distribution is similar to that 
reported in previous studies of a large group of stone patients. (Broadus, 1981) The 
serum calcium in this population was clearly above normal (JJ=11.2 mg/dL, S.D.=1.1, 
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N=3). The urinary calcium on the fixed diet (JJ=5.1 mg/kg, S.D.=1.9, N=3) was signifi¬ 
cantly higher (p<.001) than that observed in the remainder of the stone population 
(p.=3.2 mg/kg, S.D.=1.4, N=214). 50% of the patients in this group had a fixed diet ur¬ 
inary calcium greater than 4,8 mg/kg of body weight. Only 14% (31 of 214) of the 
remainder of the stone population had such a degree of hypercalciuria. 
"Garden-Variety Stone Disease" 
Hypouresis, manifested by a urine volume of less than one liter per day, was 
observed in 36 of I*!0! patients (20%). Hyperuricosuria was manifest in 57 of 17& 
patients (32%). (The urinary uric acid was not available in the case of one patient.) 
Hypercalciuria (measured on either or both of the "free" and regulated diets) was 
observed in 81 of 177 patients (45%). 
From the risk factor perspective, 136 (87%) of the 156 "garden-variety" oxalate 
stone patients for whom family histories were available manifested at least one of 
the risk factors of positive family history (stone disease in at least one first degree 
relative), hypouresis, hyperuricosuria, or hypercalciuria, with only some 13% having 
no identifiable risk factors within these categories. (See Figure Five) Of note was 
the fact that positive family history for renal stone disease was seen in patients 
manifesting each of the three treatable risk factors of hypouresis, hyperuricosuria, 
and hypercalciuria. Of those patients for whom a family history was obtained in this 
category, 12 of 23 low volume patients (43%), 22 of 42 hyperuricosurics (52%), and 32 
of 69 hypercalciurics (46%) had at least one first degree relative with a history of 
renal calculi. (See Figure Six) 
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FIGURE 5: 
Cumulative Frequency Distribution of Patients with Specific Numbers of 
Identifiable Risk Factors (Positive Family History, Low Urine Volume, 
Hyperuricc-suriai Hypercalciuria) among 156 Patients with "Garden-Variety" Calcium 
Oxalate and Mixed Oxalate Stones 
y-axis: number of patients 
150 
# of Risk Factors 4 3-4 2-4 1-4 
# of pts 1 17 70 136 
% of pts 1 11 45 87 
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FIGURE 6: 
Positive Family History Manifested among Patients with Treatable Risk Factors 
for Renal Stone Disease 
y-axis: per cent of patients with indicated risk factor who have positive family 
histories 
Low Volume Hypercalciuria Hyperuricosuria 
46% 52% 43% 

Looking at treatable risk factors alone (i.e. hypouresis, hyperuricosuria, and 
hypercalciuria), of the 179 patients with "garden-variety" stone diseasej 44 had no 
identifiable risk factors, 93 (55%) had one identifiable risk factor, 35 (20%) had two 
identifiable risk factors, and 2 (1%) were positive for all three risk factors. There 
was no correlation (p>.Q5) between the number of identifiable risk factors that the 
patients manifested and the mean number of renal stone episodes that they experi¬ 
enced per year. 
Among the 36 patients with a low urine volume, the average age of presentation 
at the stone clinic was 32. 26 (72%) were males and 10 (28%) were females. 6 (17%) of 
the 36 had coincident hyperuricosuria, and 6 (17%) had coincident hypercalciuria. 
To understand the nature of hyperuricosuria seen in stone patients, hyper- 
uricosurics from the "garden-variety" stone population were analyzed as a separate 
group. This group was made up of 52 males and 5 females. 26 (46%) were hyperuricemic 
(as defined by a serum uric acid value greater than 7.0 mg/dL in a male or greater 
than 6.0 mg/dL in a female). (Wyngaarden, 1976) The fractional excretion of Uric Acid 
(F.E.U.A.) (j-i=.076) among this group was not significantly greater (p=.109) than the 
value observed in the remainder of the stone population in whom fractional excretion 
was determined (4=.063, S.D.=.031, N=23). Serum uric acid (,U=6.8 mg/dL) was higher 
(p=.001) in this group of patients than in all other patients that were studied (]J.=6.0 
mg/dL, S.D.=1.7, N=17Q). 63% of this group had a serum uric acid level greater than 
6.2 mg/dL, while only 42% (72 of 170) of the remaining patients had such a high level. 
Dietary purine intake was also higher (p=.003) in this group of patients (j->.=156 mg) 
than in all of the other stone patients studied (JJ=114 mg, S.D.=30, N=161). 55% of this 
group had a dietary purine intake greater than 128 mg/day, while only 35% (56 of 161) 
had such a high intake. Of note is the fact that among the entire stone clinic papula- 
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tion, a positive correlation existed between Dietary Purine/kg Wt and Urinary Uric 
Acid/kg Wt, (N=221, r=.186, p=.006). 
To examine the nature of the hypercalciuria in the patients who were hypercal- 
ciuric on one or both diets, the 31 oxalate stone patients from the entire stone 
population who fulfilled these criteria were examined as one group. This group ex¬ 
cluded patients with primary hyperparathyroidism, renal tubular acidosis, 
sarcoidosis, and enteric hyperoxaluria. 56 of these 31 (63%) were found to have ab¬ 
sorptive hypercalciuria, 14 (17%) had normal calcium tolerance tests, and 11 (12%) 
were not fully evaluated, as noted in the following table: 
HYPERCALCIURIC? FREE DIET only 
Absorptive Hypercalciuria 5 
Normal Calcium Tol. Test 4 
No Work-Up 5 
TOTAL 14 
FIXED DIET only BOTH DIETS TOTAL 
22 29 56 
7 3 14 
0 6 11 
23 38 31 
There was no significant difference (p>.05) between the TmP/GFR of the absorp¬ 
tive hypercalciurics (H=3.1) and that of the non-hypercalciurics seen in the stone 
clinic (p=3.0, S.D.=0.7, N=37). Of note, there was a strong correlation (p<.001) be¬ 
tween the daily phosphorous intake per kg of body weight and the daily urinary 
phosphorous per kg of body weight output (r=.274). (See Figure Seven) In addition, 
there was a strong correlation (p<.001) among the entire stone population between 
serum phosphate and TmP/GFR (r=.656). Excluding two patients in the series with 
creatinine levels greater than 1.5, the correlation remains strong (p<.001) and the r 

value for the serum phosphate vs TmP/GFR correlation increases to .760. (See Figure 
Eight) 

FIGURE 7; 
Linear Regression Superimposed upon Scatterplot of Dietary Phosphorus vs. 
Urinary Phosphorus 
x-axis: dietary phosphorus (mg/kg Wt/day)...y-axis: urinary phosphorus (mg/kg 
Wt/day) 
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FIGURE 3: 
Linear Regression Super imposed upon Scatterplot of Serum Phosphate vs. 
TmP/GFR 
x-axis: serum phosphate (mg/dl)...y-axis: tmp/gfr 
Two patients with serum creatinine greater than 1.5 mg/dl are excluded from below 
4„§ 
4 
3.5 
3 
00 o o 
0 $ 
o!Sr"° 
ooo 
0 o 
88 o. 00 0 6/ 
o ooVoj 0 * o 
o,-' o o o 
''*8° o o 00 
o 
o 
A 
0 
—H- 
2.5 3.5 

-40- 
To examine the possibility that some patients were sensitive to dietary factors 
that might have promoted hypercalciuria, a subgroup of patients was examined in 
particular. The 23 patients who comprised this group uiere those hypercalciuric oxal¬ 
ate stone patients who did not have a primary stone-predisposing process, and who 
met at least one of the following conditions: 1) their urine calcium excretion on the 
free diet was over 50 mg higher than on the fixed intake diet (N=21), or 2) they were 
hypercalciuric on both diets, but a calcium tolerance test did not show evidence of 
absorptive hypercalciuria <N=3). The striking average decrease in calcium excretion 
in going from a low-normal calcium "free" diet to a high-normal 1000—mg defined diet 
may be easily appreciated in visual terms. (See Figure Nine) 
FIGURE 9: 
Urinary Calcium on a Low-Normal Calcium Diet vs. a High-Normal Calcium Diet in 
a Population of "Dietary Hypercalciurics" 
x-axis: low-normal diet on It, high-normal on rt...y-axis: urinary calcium (mg/day) 
125 
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In this group, there was no correlation between dietary oxalatej phosphorus! 
purinei or protein intake (p>.05) and urinary calcium excretion. Dietary sodium intake 
per kilogram body weight> howeverj was found to correlate (r=.576! p=.0045 N=23) with 
urine calcium excretion per kilogram body weight on the "free" diet. (See Figure Ten) 
FIGURE 10: 
Linear Regression Superimposed upon Scatterplot of Dietary Sodium vs. Urinary 
Calcium on Low-Normal Calcium Diet 
x-axis: dietary sodium (mg/kg weight/day)■..y-axis: urinary calcium on "free 
diet" (mg/kg weight/day) 
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Urinary sodium excretion also correlated (r=.570? p=.009) with free diet urine 
calcium for the twenty patients among the twenty-three for whom a 24-hour urine 
sodium level was available. (See Figure Eleven) 
FIGURE 11: 
Linear Regression Superimposed upon Scatterplot of Urinary Sodium vs. Urinary 
Calcium on Low-Normal Calcium Diet 
x-axis: urinary sodium (mg/day)...y-axis: urinary calcium on "free diet" (mg/day) 
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Finally, dietary calcium intake per kilogram body weight in these twenty-three 
patients was also found to correlate (r=.471 ,p=.023) with urine calcium excretion per 
kilogram body weight on the "free" diet, (See Figure Twelve) Of note, in this 
population of "dietary hypercalciurics" the good correlation between sodium (intake 
and output) and urinary calcium on the "free" diet was stronger than that between 
calcium intake and urinary calcium. 
FIGURE 12: 
Linear Regression Superimposed upon Scatterplot of Dietary Calcium vs. Urinary 
Calcium on Low-Normal Calcium Diet 
x-axis: dietary calcium (mg/kg Wt/day)...y-axis: urinary calcium on "free diet" 
(mg/kg Wt/day) 
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DISCUSSION 
There are clear limits to the usefulness of the data presented in this study. 
Because the renal stone clinic operates as a referral center? the population that it 
serves is likely to be somewhat skewed from the "average" population of stone pa¬ 
tients. As such, the patients who became part of its data base were more likely to 
represent, on the average, apparently greater degrees of stone pathology than 
patients treated solely by their primary physician. 
Cystine Stones 
Treatment of cystinuria and prevention of cystine calculi formation centers on 
monitoring the cystine excretion rate. Since in cystine stone patients that rate is 
generally higher than the maximum solubility of cytine (300 mg/L) at physiological pH, 
a primary mode of therapy is reduction of the cystine concentration in urine to below 
the 300 mg/L level. A tolerable first-line approach would be forced hydration. If 
water alone is insufficient, then alkalinization of the urine may be attempted, as 
alkalinization of the urine to a pH of greater than 7.5 can double cystine solubility. 
A concern, of course, with alkalinization is that precipitation of calcium phosphate 
stones may be enhanced. Patients for whom these conservative measures are not ful¬ 
ly effective may also be placed upon a cystine solubilizing drug such as 
D-Penicillamine. (Dahlberg, 1977) Unfortunately, this agent is quite toxic. 
MAP Stones 
Urease produces the physico-chemical conditiuns necessary for urine super¬ 
saturation with magnesium ammonium phosphate and the vast majority of Proteus iso¬ 
lates are urease-positive. In this series, as in previous ones, the occurrence of 
Proteus species as the primary organism associated with the magnesium ammonium 
phosphate stone has obtained. 
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An important point to be noted is that the majority of stone patients with mag¬ 
nesium ammonium phosphate stones present with a urine culture colony count of less 
than IOOjOOO per milliliter. Examples of such low levels of organism counts have been 
reported previously out of the Mayo Clinic series. (Smith, 1976) Consequently, dismis¬ 
sal of a "negative" culture may cause a hasty clinician to ignore this potentially 
treatable and sometimes morbid form of renal stone disease. Because these stones 
may form secondarily to stasis or a "foreign body" focus caused by other stone 
types, an always essential first-step is to screen the patient for other risk factors 
and to treat those appropriately. Unfortunately, unless MAP stone material is com¬ 
pletely removed or passed, it can serve as a nidus for stone recrudescence. 
Therefore, successful surgical therapy requires the complete removal of all stone 
material. Such procedures are often difficult and only partially successful. (Griffith, 
1973) Other treatment regimes via diet or medication are still either experimental, 
impractical, or unavailable. (Broadus, 1981) 
Uric Acid Stones 
Because this group of patients had a highly significant (P=.0G3) lower urine vol¬ 
ume than the rest of the stone population, weight is added to the hypothesis of some 
investigators that hypouresis is an independent risk factor for the formation of uric 
acid calculi specifically. What has not been explained is why uric acid stone 
formation should be especially sensitive to urine volume. (Broadus, 1981) The import¬ 
ance of hyperuricosuria as a risk factor was confirmed likewise. No evidence was 
found for differing fractional excretion of uric acid levels contributing to the forma¬ 
tion of this type of stone. Because the average urine uric acid was 656 mg/L and uric 
acid solubility varies from about 100 mg/L at pH=5 to about 1500 mg/L at pH=7, the 
critical role that urinary pH can play in the formation of uric acid stones is evident. 
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In an acid urine, the stone patient would be much more likely to precipate his urinary 
uric acid than he would be in an alkaline urine. (Broadus, 1381) That one of the pa¬ 
tients in this subgroup (17%) had Crohn's disease is meaningless in itself, but it does 
point out the increased association between inflammatory bowel disease and uric 
acid stone formation. (Broadus, 1381) 
With the population of uric acid stone formers tending to underproduce urine 
chronically, forced hydration would seem to be the first step in rational treatment. 
For patients producing a persistently acid urine, alkalinization with sodium bicarbon¬ 
ate may also be attempted, although patient compliance is often poor. (Broadus, 
1381) In patients with marked hyperuricosuria, or a severe history of stone disease, 
allopurinol has become the drug of choice in many uric acid stone patients. An ana¬ 
logue of hypoxanthine, it is a competitive inhibitor of xanthine oxidase, decreasing 
uric acid overproduction and excretion. (Holmes, 1380) 
Calcium Phosphate Stones 
As demonstrated by this study, an alkaline urine can be an important variable in 
the pathogenesis of calcium phosphate stones. That the difference in urine alkalinity 
holds up even when an obvious source of an alkaline urine factored out suggests the 
importance of the association of an alkaline urine and "idiopathic" calcium phos¬ 
phate stones. Patients with complete distal renal tubular acidosis are treated with 
alkali in sufficient quantities so as to increase to normal their serum bicarbonate 
concentration. (Broadus, 1381) When alkali abuse resulting in a "milk-alkali" syndrome 
or an acetazolamide induced secondary renal tubular acidosis is suspected, then it 
would seem appropriate to withdraw these medications from a patient's treatment 
regimen. If other risk factors for stone disease (e.g hypouresis, hypercalciuria) are 

also present, these, too, should be investigated and, it would seem, be treated 
appropriately. 
Calcium Oxalate Stones 
As suggested above, rational approaches to the understanding of 
garden-variety calcium stones might benefit from understanding the underlying type 
of stone disease that the patient has. An initial determination would be whether the 
calcium oxalate stone is a secondary manifestation of a primary disease such as pri¬ 
mary hyperparathyroidism, distal renal tubular acidosis, enteric hyperoxaluria, or 
sarcoidosis. Presumably, treatment of the underlying disease would head off the for¬ 
mation of stones. Once a primary disease has been ruled out, the risk factor 
approach can prove most useful. In this series, a risk factor for calcium oxalate 
stone disease could be identified in over three-fourths of patients with the 
garden-variety type of stone. With low urine volumes, hypercalciuria, and hyper¬ 
uricosuria all being potentially modifiable, theoretical understanding of risk factors 
might be usefully applied to reducing risk of recurrent stone formation. Patients pro¬ 
ducing a urine volume of below one liter per day might be instructed to increase their 
water intake regularly. Dietary modifications may also be made. Unnecessary phar¬ 
macologic doses of Vitamin C should be eliminated from the patient's intake. (Smith, 
1973) Because it is metabolized to oxalic acid, the removal of excess Vitamin C can 
lead to a significant decrease in oxalate excretion through the urine. 
For the risk factor of hyperuricosuria associated with calcium oxalate stones, 
several important points may be made. The fractional excretion of uric acid is no 
greater in the "garden-variety" stone-formers with hyperuricosuria than in the re¬ 
mainder of the stone population. Nevertheless, their level of serum uric acid and 
their average level of purine intake is higher than that of the remainder of the stone 
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population. In addition, the correlation between dietary purine/kg Wt and urinary uric 
acid/kg Wt is highly significant for the entire stone population Cp=.Q06). Taken 
together, these facts suggest (but, of course, do not prove) that the hyperuricosuria 
seen in the calcium oxalate stone population is not caused by a defect in the excre¬ 
tion of uric acid, but rather reflects purine gluttony. Although treatment modalities 
were beyond the scope of this study, if this hypothesis were true, it would provide a 
rational explanation for the so-called "Western diet" acting to predispose patients 
to renal calculi. Presumably, if this hypothesis were true, hyperuricosuric calcium 
oxalate stone formers might be able to reduce the degree of or eliminate one of their 
risk factors for stones by modifying their dietary intake of purines. In practice, 
most such patients are treated with allopurinol. 
The pathophysiological mechanisms responsible for "idiopathic" hypercalciuria 
are controversial. In the present series, the majority of hypercalciuric patients dis¬ 
played evidence of the specific syndrome of so-called absorptive hypercalciuria. As 
an extension of the present series, these patients were evaluated in detail, and an 
increase in circulating l,25-(OH)^D, the hormonal form of vitamin D responsible for 
<L 
the regulation of intestinal calcium transport, was observed in eighty per cent of 
patients. (Broadus, 1984) The "phosphate-leak" hypothesis is a recent proposal put 
forth to explain this constellation of findings. In essence, this hypothesis holds that 
the primary abnormality in affected patients is a proximal tubular "leak" of phos¬ 
phate, leading to secondary stimulation of l,25-(0H)oD synthesis (known to be 
sensitive to hypophosphatemia) and the remaining features of the syndrome. The 
findings of this series do not support this hypothesis, in that a tendency toward a 
reduction in TmP/GFR and hypophosphatemia was found in both hypercalciuric and 
non-hypercalciuric patients, indicating that hypophosphatemia could not regularly 
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and/or statistically be related to circulating l,25-(0H)oD or, in fact, even hypercal- 
ciuria, in patients with calcium oxalate stone disease. (Broadus, 1334) Although this 
point is controversial (Tschope, 1380), the findings in this series in this regard are 
in agreement with the only other large series in which this question was examined 
systematically. (Edwards, 1365) Based on these and other observations in patients 
with this syndrome, an alternate pathogenetic theory has been proposed. (Broadus, 
1384) 
There is no consensus regarding optimal medical therapy for the treatment of 
this form of hypercalciuria. (Broadus, 1381) Diet may be approached through an in¬ 
creased fluid and a decreased (about 400 mg/day) calcium intake. It is possible that 
a restriction in calcium intake may be physiologically compensated for by an in¬ 
creased oxalate absorption and excretion—so negating potential benefits of 
reducing calcium intake alone. (Broadus, 1331) Sodium cellulose phosphate, which is 
nonabsorbable and can complex with calcium, has been reported to be effective in 
reducing calcium excretion in patients with absorptive hypercalciuria. (Pak, 1374) If 
all other approaches fail, therapy may also be instituted empirically. Thiazides have 
been reported highly effective in moderating undifferentiated hyperoxaluria and hy¬ 
percalciuria, and oral phosphorus has been reported to increase the excretion of 
pyrophosphate, an inhibitor of stone formation and growth. (Yendt, 1378, Thomas, 
1378, Pak, 1373) 
The identification of a subpopulation of "dietary hypercalciurics" is an extreme¬ 
ly important component if one wishes to appreciate the nature of hypercalciuria. In 
this series "dietary hypercalciurics" were defined among the garden-variety calcium 
oxalate stone population as being those hypercalciuric patients whose 24 hour calci¬ 
um excretion on a free diet was at least 50 mg than their calcium excretion on a 

fixed 1000-mg calcium diet or who met the condition that they be hypercalciuric on 
both the fixed and free diets* yet have a normal response to a calcium tolerance 
test. This population excretes an especially high level of calcium on a diet that on 
the basis of its calcium content alone should not predispose to hypercalciuria. If the 
statistical association between dietary sodium intake and urinary calcium excretion 
on a free intake diet that was established in this group bears out in physiological 
terms* then it would seem that their hypercalciuria might partially result from die¬ 
tary factors. In particular, a high sodium diet would tend to predispose patients in 
this subpopulation to hypercalciuria and, presumably, renal calculi. If the converse 
of this hypothesis is true, then a restricted sodium diet in this group of patients 
might reduce urine calcium excretion and, presumably, decrease a patient's chances 
of developing renal calculi. 
Possibly, by eliminating as many risk factors as possible, calcium oxalate stone 
disease, indeed, most renal stones, might largely be prevented. 
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APPENDIX ONE—NUMERICAL DATA 
All Patients: 
Category 
Age at First Episode (yrs) 
Frequency of Episodes (#/yr) 
Serum Calcium (mg/di) 
Serum Uric Acid (rng/dl) 
Serum Phosphate (mg/dl) 
Serum Carbon Dioxide (mEq/L) 
Serum Chloride (mEq/L) 
Dietary Calcium (mg/day) 
Dietary Calcium (mg/kg Wt/day) 
Dietary Oxalate (mg/day) 
Dietary Oxalate (mg/kg Wt/day) 
Dietary Liquid (ml/day) 
Dietary Liquid (ml/kg Wt/day) 
Dietary Purine (mg/day) 
Dietary Purine (mg/kg Wt/day) 
Dietary Protein (g/day) 
Dietary Protein (g/kg Wt/day) 
Dietary Sodium (mg/day) 
Dietary Sodium (mg/kg Wt/day) 
Dietary Phosphorus (mg/day) 
Dietary Phosphorus (mg/kg Wt/day) 
Number Mean Std Dev 
226 34 12 
217 2 4 
223 3.6 0.6 
227 6.2 1.7 
223 3.2 0.5 
228 26.1 3.1 
228 104 3 
217 563 330 
217 7.7 4.7 
217 47 51 
217 0.67 0.37 
135 2014 342 
135 28 13 
217 123 34 
217 1.7 1.3 
217 83 35 
217 1.20 0.43 
217 2175 1215 
217 23.4 18.1 
216 1225 516 
216 16.5 6.3 

Urine Volume (ml/day) 
"Free" Urine Calcium (mg/day) 
"Free" Urine Calcium (mg/kg Wt/day) 
"Fixed" Urine Calcium (mg/day) 
"Fixed" Urine Calcium (mg/kg Wt/day) 
Urine Sodium (mEq/day) 
Urine Sodium (mEq/kg Wt/day) 
Fractional Excretion of Uric Acid 
Urine Uric Acid (mg/day) 
Urine Uric Acid (mg/kg Wt/day) 
Urine Oxalate (mg/day) 
Urine Oxalate (mg/kg Wt/day) 
Urine Phosphorus (mg/day) 
Urine Phosphorus (mg/kg Wt/day) 
Low Urine pH 
Mean Urine pH 
TmP/GFR 
Urine Culture (Organisms/ml) 
229 1607 803 
227 229 117 
227 3.05 1.51 
222 243 114 
222 3.30 1.50 
113 150 73 
113 1.95 0.85 
33 0.063 0.03: 
223 669 251 
223 3.33 3.08 
31 55 38 
31 0.75 0.54 
222 959 401 
222 12.7 4.7 
223 5.3 0.6 
109 5.8 0.7 
203 3.1 0.7 
203 11300 74000 
Magnesium Ammonium Phosphate Stone Patients: 
Category Number 
9 
Mean 
1771 
Std Dev 
334 Urine Volume (ml/day) 

Free" Urine Calcium (mg/day) 115 9 
"Free" Urine Calcium (mg/kg Wt/day) 9 
"Fixed" Urine Calcium (mg/day) 9 
"Fixed" Urine Calcium (mg/kg Wt/day) 9 
Urine Uric Acid (mg/day) 9 
Urine Phosphorus (mg/day) 9 
TmP/GFR 9 
Urine Culture (Organisms/ml) S 
196 
2.3 
190 
2.5 
611 
1029 
2.4 
45600 
1.7 
173 
1.3 
272 
573 
0.6 
47300 
Uric Acid Stone Patients: 
Category Number 
Serum Calcium (mg/dl) 6 
Serum Uric Acid (mg/dl) 6 
Urine Volume (ml/day) 6 
"Free" Urine Calcium (mg/day) 6 
"Free" Urine Calcium (mg/kg Wt/day) 6 
"Fixed" Urine Calcium (mg/day) 6 
"Fixed" Urine Calcium (mg/kg Wt/day) 6 
Fractional Excretion of Uric Acid 2 
Urine Uric Acid (mg/day) 6 
6 
Mean 
9.7 
7.0 
1000 
157 
2.0 
239 
3.0 
0.035 
656 
3.0 
Std Dev 
0.4 
2.0 
378 
67 
0.8 
124 
1.7 
321 
0.6 TmP/GFR 
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Cystine Stone Patients: 
Category Number Mean Std Dev 
Serum Calcium (rng/dl) 3 9.6 0.4 
Urine Volume (ml/day) 3 1160 299 
"Free" Urine Calcium (mg/day) 3 156 125 
"Free" Urine Calcium (mg/kg Wt/day) 3 1.9 1.5 
Urine Cystine (mg/day) 3 811 564 
Urine Uric Acid (mg/day) 3 378 649 
TmP/GFR O i- 3.9 
Calcium Phosphate Stone Patients: 
Category Number Mean Std De 
Serum Calcium (mg/dl) 17 9.5 0.4 
Serum Carbon Dioxide (mEq/L) 17 25.2 3.0 
Urine Volume (ml/day) 17 1361 513 
"Free" Urine Calcium (mg/day) 17 242 141 
"Free" Urine Calcium (mg/kg Wt/day) 17 3.3 1.8 
"Fixed" Urine Calcium (mg/day) 17 231 104 
"Fixed" Urine Calcium (mg/kg Wt/day) 17 3.3 1.4 

Mean Urine pH 11 6.0 0.3 
Urine Uric Acid (mg/day) 17 602 205 
Urine Phosphorus (mg/day) 17 878 280 
T mP/GFR 14 2.8 0.3 
Calcium Phosphate Stone Patients 
Acetazolarnide Ingestion: 
without RTAj or a History of Antacid Abi 
Category Number Mean Std Dev 
Urine Volume (ml/day) 12 1337 548 
Mean Urine pH 7 6.1 0.2 
"Free" Urine Calcium (mg/day) 12 248 145 
"Free" Urine Calcium (mg/kg Wt/day) 12 3.4 1.9 
"Fixed" Urine Calcium (mg/day) 12 282 115 
"Fixed" Urine Calcium (mg/day) 12 3.9 1.6 
Urine Uric Acid (mg/day) 12 613 115 
Urine Phosphorus (mg/day) 12 863 240 
TmP/GFR 10 2.9 0.9 
Calcium Oxalate Stone Patients with Sarcoidosis: 

Category Number Mean 
Serum Calcium (mg/dl) 2 10.2 
Serum Uric Acid (mg/dl) 2 8.4 
Serum Phosphate (mg/dl) 2 3.2 
Urine Volume (ml/day) 2 1750 
"Free" Urine Calcium (mg/day) 188 
"Free" Urine Calcium (mg/kg Wt/day) O 2.78 
"Fixed" Urine Calcium (mg/day) V i- 365 
"Fixed" Urine Calcium (mg/kg Wt/day) 2 5.17 
Urine Uric Acid (mg/day) 2 632 
Urine Phosphorus (mg/day) 2 1240 
Std Dev 
Calcium Oxalate Stone Patients with Enteric Hyperoxaluria: 
Category Number Mean Std Dev 
Serum Calcium (mg/dl) 
Urine Volume (ml/day) 
"Free" Urine Calcium (mg/day) 
"Free" Urine Calcium (mg/kg Wt/day) 
"Fixed" Urine Calcium (mg/day) 
"Fixed" Urine Calcium (mg/kg Wt/day) 
Urine Uric Acid (mg/day) 
8 9.3 0.5 
8 1231 316 
8 147 71 
8 2.1 1.1 
8 119 26 
8 1.7 0.5 
8 514 126 
8 7.14 2.24 Urine Uric Acid (mg/kg Wt/day) 

Urine Phosphorus (mg/day) 
Urine Phosphorus (mg/kg Wt/day) 
Urine Oxalate (mg/day) 
Urine Oxalate (mg/kg Wt/day) 
TmP/GFR 
8 703 280 
8 9.98 5.01 
5 74 19 
5 1.0 0.3 
8 3.2 0.87 
Calcium Oxalate Stone Patients with Primary Hyperparathyroidism: 
Category Number 
Serum Calcium Cmg/dl) 9 
Urine Volume (ml/day) 9 
"Free" Urine Calcium (mg/day) 10 
"Free" Urine Calcium (mg/kg Wt/day) 10 
"Fixed" Urine Calcium (mg/day) 8 
"Fixed" Urine Calcium (mg/kg Wt/day) 8 
Urine Uric Acid (mg/day) 10 
Urine Phosphorus (mg/day) 9 
TmP/GFR 7 
Mean 
11.2 
1577 
326 
;.9 
396 
714 
1102 
2.7 
Std Dev 
1.1 
571 
154 
1.3 
I 
1.9 
'68 
563 
0.7 
Garden-Variety Calcium Oxalate Stones: 
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Category Number Mean Std Dev 
Serum Calcium (mg/dl) 179 9.6 0.5 
Urine Volume (ml/day) 179 1644 844 
"Free" Urine Calcium (mg/day) 178 233 111 
"Free" Urine Calcium (mg/kg Wt/day) 178 3.1 1.4 
"Fixed" Urine Calcium (mg/day) 177 251 105 
"Fixed" Urine Calcium (mg/kg Wt/day) 177 3.3 1.4 
Urine Uric Acid (mg/day) 178 679 242 
Urine Uric Acid (mg/kg Wt/day) 178 8.9 3.0 
Urine Phosphorus (mg/day) 173 933 401 
Urine Phosphorus (mg/kg Wt/day) 173 12.8 4.6 
Urine Oxalate (mg/day) 31 40 43 
Urine Oxalate (mg/kg Wt/day) 31 0.53 0.60 
TmP/GFR 160 3.1 0.7 
Calcium Oxalate Stone Patients with Low Urine Volume: 
Category Number Mean Std Dev 
Age at First Stone Event (Years) 36 32 10 
Urine Volume (ml/day) 36 1022 338 
"Free" Urine Calcium (mg/day) 36 166 71 
"Free" Urine Calcium (mg/kg Wt/day) 36 2.32 0.97 
"Fixed" Urine Calcium (mg/day) 35 189 62 

"Fixed" Urine Calcium (mg/kg Wt/day) 35 2.67 0.39 
Urine Uric Acid (mg/day) 36 578 215 
Urine Uric Acid (mg/kg Wt/day) 36 3.16 3.35 
Urine Phosphorus (mg/day) 34 366 428 
Urine Phosphorus (mg/kg Wt/day) 34 
Calcium Oxalate Stone Patients with Hyperuricos 
12.1 
uria: 
5.6 
Category Number Mean Std Dev 
Serum Calcium (mg/dl) 57 9.6 0.4 
Serum Uric Acid (mg/dl) 57 6.3 1.6 
Dietary Purine (mg/kg Wt/day) 56 1.3 1.4 
Dietary Purine (mg/day) 56 156 104 
Urine Volume (ml/day) 57 2030 1112 
Urine Uric Acid (mg/day) 57 956 152 
Fractional Excretion of Uric Acid 16 0.076 0.034 
Urine Phosphorus 57 1246 458 
"Free" Urine Calcium (mg/day) 57 267 123 
"Fixed" Urine Calcium (mg/day) 57 261 113 
Calcium Oxalate Stone Patients with Absorptive Hypercalciuria: 
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Category Number Mean Std Dev 
Serum Phosphate (mg/dl) 56 3.1 0.5 
Urine Volume (ml/day) 56 1780 794 
"Free" Urine Calcium (mg/day) 56 308 97 
"Fixed" Urine Calcium <mg/day) 56 331 81 
Urine Uric Acid (mg/day) 56 675 219 
Urine Phosphorus (mg/day) 56 1018 397 
TmP/GFR 56 3.1 0.7 
Calcium Oxalate Stone Patients with Dietary Hy percalciuria: 
Category Number Mean Std Dev 
Urine Volume (ml/day) 23 1962 937 
"Free" Urine Calcium (mg/day) 23 394 89 
"Fixed" Urine Calcium (mg/day) 23 285 80 
Urine Uric Acid (mg/day) 23 800 250 
Urine Phosphorus (mg/day) 23 1191 376 
TmP/GFR 20 3.0 0.8 

APPENDIX TWO—METHODS AND FORMS 
Initial contact with patients occurred by telephone. On this important occasion 
the patients were instructed as to what to expect in the evaluation of his stone dis¬ 
ease. They were told that they would be sent a 24-hour urine specimen container, 
which they were to bring with them to their first clinic appointment. They were also 
sent the "Diet History Instruction Form" (see following page) which told them how to 
record their dietary intake. Finally, they were instructed to arrive at his first renal 
stone clinic visit in a state of fasting, so that the initial screening tests of blood 
and urine were on standardized samples. 
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DIET HISTORY INSTRUCTION FORM 
1. You are to write down everything you eat and drink for a period of three days 
that you consider to be representative of what you usually eat, with attention 
to the following: 
a. The three days do not need to be consecutive. 
b. One of the days you keep a record of what you eat and drink should be the 
same day you do a 24 hour collection of urine (please specify this day clearly in 
your booklet). 
Use this booklet to keep a record of your food intake. 
Include the complete amounts you eat and what time you eat. 
4. Estimate the portion size of all foods and list measures for all items. For 
example, an average size chicken leg is about 3 oz. of meat, while 1 slice of cold 
cuts is about 1 oz. of meat. All beverages, canned fruits, vegetables and cereals 
should be measured with a measuring cup, not a coffee cup. 
5. Be sure to include butter, margarine or fat if used with vegetables or bread! 
gravies or sauces? condiments such as mustard, catsup, mayonnaise or salad 
dressings! and milk, cream or sugar used in coffee or tea and on cereal. 
Here is an example: 
7:00 A.M. 
10:00 A.M. 
12:00 Noon 
3:15 P.M. 
Vi grapefruit with 2 teaspoons of sugar 
1 egg 
2 strips bacon 
1 toast with 1 teaspoon butter 
1 cup coffee with 2 tablespoons of evaporated milk and 
2 teaspoons of sugar 
1 sweet roll with 1 pat margarine 
1 large fried hamburger 
Vi cup mashed potatoes with 2 tablespoons gravy 
Vi cup peas with 1 teaspoon of margarine 
1 glass (8 oz.) milk 
Vi cup fruit cocktail 
2 chocolate filled cookies 
Mounds candy bar 
If you encounter any problems or have questions concerning your recall, please 
call during Tuesday morning clinic hours and ask to speak to the dietitian 
regarding your diet. The phone number is (203)-43S-8060. 
6. 
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On arrival at the renal stone clinic, the patient is given a copy of the form 
reproduced below: 
"FIRST RENAL STONE CLINIC VISIT" 
Your first Renal Stone Clinic visit is designed to obtain: 
a) A clinical history and physical examination by the physician. 
b) A detailed dietary history obtained by the nutritionist. 
c) Initial screening tests of blood and urine. 
d) The initiation of a search for a history of kidney stones in your family. 
In addition, your initial visit is designed to allow for further diagnostic 
laboratory testing under optimum conditions. This testing includes: 
a) Collection of two 24-hour urine specimens while you are eating a defined 1000 
mg calcium diet. 
b) Many patients will have an x-ray examination (either plain x-rays of the 
kidneys or an intravenous pyelogram). If you are to have any type of kidney x-ray, 
you will be given a packet of material concerning preparation for this x-ray. Please 
note that this preparation would interfere with the 24-hour urine collections, so that 
in no case should a 24-hour specimen of urine be collected during preparation for 
x-rays. For patients living in the metropolitan New Haven area, the x-rays will be 
scheduled at a time several or more days distant from the urine collections. For 
patients coming from a longer distance, the 24-hour specimens may be collected and 
refrigerated for a day during which time the preparation for x-rays is taking place 
(in this case begin the x-ray preparation the day before the scheduled x-ray rather 
than following the two day instructions included in the packet). 
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RENAL STONE CLINIC H & P FORM 
I. Name: 
Address: 
Telephone number: 
Age: 
Sex: 
II. Referring physician: 
Address: 
Telephone number: 
III. Clinical stone events. Specify date, side, and type (passed, removed, historical 
event, or radiologic new stone) of each event. 
Total number_Stones per patient year_Bilateral?_ 
IV. Previous evaluation: 
a. Stone analysis (% composition, laboratory name): 
b. Chemistries: 
c. C & S and pH: 
d. IVP: 
e. Date and findings on last x-ray: 
V. Prior treatment. Specify when instituted, estimate of compliance, and estimate 
of benefit. 
a. Forced fluids: 
b. Diet: 
c. Medication: 
d. Present or recent medications (when discontinued): 
VI. Past history: 
a. Childhood illnesses: 
b. Adult illnesses: 
c. Hospitalizations: 
d. Operations: 
e. Allergies: 
VII. Clinical and social history. 
a. Abnormal serum or urinary calcium: 
b. Abnormal serum or urinary uric acid: 
c. Hyperparathyroidism: 
d. Gout: 
e. Ulcer disease (dyspepsia): 
f. Antacid intake: 
g. Analgesic intake: 
h. Vitamin intake: 
i. Chronic diarrhea: 
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j. Hypertension: 
k. Kidney or bladder infection: 
l. Osteoporosis, bone pain, fractures: 
•ffi. Sun exposure: 
n. Periods of dehydration: 
o. Work: 
P. Smoking: 
q. Ethanol: 
Comments and/or Review of Systems: 
VIII. Dietary summary: 
IX. Family history summary: 
X. Physical examination: 
1. HEENT: 
2. Chest: 
3. Abdomen: 
4. Genitalia: 
5. Extremities: 
6. Neurologic: 
XI. Summary: 
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At the conclusion of the first stone clinic appointment, the patient is given a 
detailed instruction form explaining the procedure for collecting a 24-hour urine on a 
defined 1000 mg calcium intake: 
"INSTRUCTIONS FOR TWO 24-HOUR URINE COLLECTIONS ON A 1 000 MG CALCIUM 
INTAKE" 
1. These collections are ideally performed on the weekend following your first 
Renal Stone Clinic visit, and the detailed instructions below assume that you intend 
to collect these specimens on the weekend. Any equivalent period of time is 
satisfactory, and you may modify the instructions below for your own convenience. 
2. Friday morning (1 day before beginning the urine collections) begin eating the 
diet on which you were instructed by the nutritionist. Also begin to take the calcium 
gluconate tablets, two tablets with each meal (6 tablets per day). Please note that 
these tablets are large and should be chewed to a fine powder before swallowing. 
Continue the diet and the calcium tablets on Saturday and Sunday, the two days of 
urine collections. 
3. Estimate what time you will get up on the following Monday morning, and write 
this time in the three blanks below. 
SATURDAY 
4. _a.m.: Void into the toilet as usual. (You may go back to bed after voiding). 
The next time you void, collect the urine into a clean container and pour it carefully 
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in to one of the collection jugs. The collection jugs contain an acid preservative, so 
that you should not void directly into them. Continue to collect all urine passed! 
refrigerate the collection bottle during and after completion of the collection. 
SUNDAY 
5. _a.m.: Void and add this urine to the same bottle you were using on 
Saturday! this completes the first 24-hour specimen. The next time you void, pour the 
urine into a new collection jug. Continue to collect all urine passed, and refrigerate 
the specimen. 
MONDAY 
6. _a.m.: Void and add this urine to the bottle you were using on Sunday! this 
completes the second 24-hour specimen. 
7. Label each bottle carefully with the date of the collection (e.g. 
3/1 7-3/18/77). 
8. The collection jugs should be returned to the clinic on DANA III. Please do not 
eat or drink anything before bringing the specimens to the clinic! you are scheduled 
to have a blood specimen drawn on the same morning. 
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FLOW DIAGRAM AND DATA BASE DERIVED FROM THE ORAL CALCIUM TOLERANCE 
TEST (BROADUS, 1378, 1981) 
ORAL CALCIUM TOLERANCE TEST 
I. HOW DIAGRAM 
CONTROL 
—r~ 120" LAG 1 240’ EXPERIMENTAL 1 360‘ 
PERIOD U) TIME U2 PERIOD U3 
II. QATA BASE 
A STATIC MEASUREMENTS (CONTROL PERIOD) 
1 BASAL SERUM CALCIUM & PHOSPHOROUS 
2 FASTING CALCIUM EXCRETION 
3. FASTING TMP/GFR 
4. BASAL NEPHROGENOUS OR TOTAL cAMP EXCRETION 
5. BASAL VITAMIN 0 METABOLITES 
B. DYNAMIC MEASUREMENTS (EXPERIMENTAL VS CONTROL PERIOD), 
1 CALCEHIC RESPONSE AS INDEX OF “CALCIUM TOLERANCE" 
2. CALCIUR1C RESPONSE (a mg CALCIUM/IOO ML GF) AS INDEX OF G! AbSORPTION 
3. SUPPRESSIBILITT OF NEPHROGENOUS OR TOTAL cAMP EXCRETION 
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Patients were prepared for the calcium tolerance test test by following a res¬ 
tricted (about 400 mg/day) calcium diet for ten days prior to testing and by fasting 
except for distilled water beginning at 8 p.m. the night before the test began. Pa¬ 
tients were hydrated with 8 ounces of distilled water semi-hourly, beginning at 7 a.m. 
and continuing through the completion of the test. At 7 a.m., the urine was voided and 
discarded. At 8 a.m., a serum calcium specimen was obtained. At 9 a.m. a urine speci¬ 
men was obtained. An oral dose of approximately one gram of elemental calcium 
(administered as 35 ml of calcium glubionate syrup plus 8 ounces of lactase-treated 
milk) was administered at 9 a.m., immediately following the first urine collection. At 
11 a.m. a urine sample was collected and discarded. At 12 noon, another serum sample 
was obtained. The test finally concluded with a last urine collection at 1 p.m.. Except 
for voiding, the patients remained inactive betwee 8 a.m. and 1 p.m. on the test day. 
The three collection periods represented a fasting control period, a two-hour lag 
period in which peak calcium absorption could occur, and an experimental period that 
demonstrated the maximal systemic affects of the absorbed calcium. The calciuric 
response was calculated by subtracting the rate of calcium excretion during the con¬ 
trol period from that during the experimental period. Calcium excretion rates were 
calculated by using the formula: CaE=Urine Calcium X Serum Creatinine/Urine Creati¬ 
nine. The upper-normal limit for the calciuric response is 0.2 mg calcium per 100 ml 
GF. Absorptive hypercalciuria was diagnosed in patients who met the following cri¬ 
teria: 1) Calcium excretion rate greater than 300 mg/day and/or greater than 4 
mg/kg/day on the 1000-mg calcium diet, 2) Hyperabsorption of calcium (as measured 
by the calciuric response to the calcium tolerance test, and 3) normal or suppressed 
parathyroid function in the fasting state (Nephrogenous cAMP less than 2.7 nmol/dL 
GF). (Broadus, 1984) Total urinary cAMP was determined with the formula: Total 
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UcAMP=Urinary cAMP X Serum Creatinine/Urine Creatinine. Nephrogenous cAMP was 
determined by subtracting the plasma cAMP level (i.e. the filtered load of cAMP) from 
the total amount of cAMP excreted. 
Data were analyzed by means of the unpaired t-test and univariate linear 
regression, all performed on the CLINFO system at the Clinical Research Center at 
the Yale-New Haven Medical Center. 
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